<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    51664
   </pmid>
   <datecreated>
    <year>
     1975
    </year>
    <month>
     12
    </month>
    <day>
     11
    </day>
   </datecreated>
   <datecompleted>
    <year>
     1975
    </year>
    <month>
     12
    </month>
    <day>
     11
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     11
    </month>
    <day>
     18
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0007-1447
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       3
      </volume>
      <issue>
       5984
      </issue>
      <pubdate>
       <year>
        1975
       </year>
       <month>
        Sep
       </month>
       <day>
        13
       </day>
      </pubdate>
     </journalissue>
     <title>
      British medical journal
     </title>
     <isoabbreviation>
      Br Med J
     </isoabbreviation>
    </journal>
    <articletitle>
     Treatment of superficial thrombophlebitis: a randomized, bouble-blind trial of heparinoid cream.
    </articletitle>
    <pagination>
     <medlinepgn>
      614-6
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext>
      In a prospective, double-blind, randomized trial the efficacy of a heparinoid in ointment form was assessed in treating superficial thrombophlebitis developing after continuous intravenous infusion. One hundred surgical patients were studied, and clinical examination and the iodine-125-labelled fibrinogen test used to assess the results. The mean time required for the relief of local symptoms and signs and the rate of local decline in radioactivity differed significantly between patients receiving the heparinoid cream and those recieving the placebo.
     </abstracttext>
    </abstract>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Mehta
      </lastname>
      <forename>
       P P
      </forename>
      <initials>
       PP
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Sagar
      </lastname>
      <forename>
       S
      </forename>
      <initials>
       S
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Kakkar
      </lastname>
      <forename>
       V V
      </forename>
      <initials>
       VV
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     ENGLAND
    </country>
    <medlineta>
     Br Med J
    </medlineta>
    <nlmuniqueid>
     0372673
    </nlmuniqueid>
    <issnlinking>
     0007-1447
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Heparinoids
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Placebos
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      9001-32-5
     </registrynumber>
     <nameofsubstance>
      Fibrinogen
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="Cites">
     <refsource>
      Gynaecologia. 1954 Jul;138(1):13-20
     </refsource>
     <pmid version="1">
      13200887
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Hippokrates. 1960 Oct 31;31:699-700
     </refsource>
     <pmid version="1">
      13747986
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1960 Sep 17;2(7151):627-30
     </refsource>
     <pmid version="1">
      13841765
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Med Klin. 1951 Jul 20;46(29):798-9
     </refsource>
     <pmid version="1">
      14862844
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Ann Paediatr Fenn. 1965;11(4):186-9
     </refsource>
     <pmid version="1">
      4159262
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Med Welt. 1967 Dec 30;52:3179-83
     </refsource>
     <pmid version="1">
      5609930
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Med Welt. 1969 Jul 26;30:1662-5
     </refsource>
     <pmid version="1">
      4187744
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1970 Mar 14;1(7646):540-2
     </refsource>
     <pmid version="1">
      4190352
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Arzneimittelforschung. 1967 May;17(5):591-3
     </refsource>
     <pmid version="1">
      4232635
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Nord Med. 1967 Apr 6;77(14):444-5
     </refsource>
     <pmid version="1">
      5336082
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Br J Clin Pract. 1970 May;24(5):197-200
     </refsource>
     <pmid version="1">
      5451928
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Arzneimittelforschung. 1969 Jan;19(1):75-9
     </refsource>
     <pmid version="1">
      4182978
     </pmid>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Administration, Topical
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adolescent
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Adult
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Clinical Trials as Topic
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Evaluation Studies as Topic
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Female
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Fibrinogen
     </descriptorname>
     <qualifiername majortopicyn="N">
      metabolism
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Heparinoids
     </descriptorname>
     <qualifiername majortopicyn="Y">
      administration &amp; dosage
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Placebos
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Thrombophlebitis
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
     <qualifiername majortopicyn="N">
      metabolism
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Time Factors
     </descriptorname>
    </meshheading>
   </meshheadinglist>
   <otherid source="NLM">
    PMC1674425
   </otherid>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      1975
     </year>
     <month>
      9
     </month>
     <day>
      13
     </day>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      1975
     </year>
     <month>
      9
     </month>
     <day>
      13
     </day>
     <hour>
      0
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      1975
     </year>
     <month>
      9
     </month>
     <day>
      13
     </day>
     <hour>
      0
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     51664
    </articleid>
    <articleid idtype="pmc">
     PMC1674425
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

